While the Industry Scrambles to Adapt, Drexi Is Already Delivering

Built on transparency, global access, and member-first pricing, Drexi is already delivering the savings and accountability others are just now chasing.

When American Patients Pay the Price for Global Profits

The United States has less than 5 percent of the world’s population, yet it funds nearly 75 percent of global pharmaceutical profits. Drug manufacturers routinely discount medications to secure access to foreign markets, then pass the financial burden onto American patients and payers. In effect, U.S. families are subsidizing lower drug prices abroad, even though pharmaceutical companies benefit from generous taxpayer-funded research and government healthcare spending.

At the same time, the affordability crisis continues to worsen:

• Nearly 1 in 4 Americans say they have difficulty affording their prescription medications.
• About 30 percent of adults report not taking their medications as prescribed due to cost, including skipping doses or not filling prescriptions at all.
• Americans pay more than three times what people in other developed nations pay for the same brand-name drugs.

The system is broken. Employers are frustrated. Members are suffering. The demand for change can no longer be ignored.

A Federal Response: Executive Order on Drug Pricing Reform

In response to growing public demand for lower prescription costs, President Donald Trump signed a new Executive Order focused on bringing drug prices in line with those paid by other wealthy nations. The order outlines several urgent actions:

• The U.S. Trade Representative and Secretary of Commerce are instructed to take action against international pricing practices that drive up costs in the U.S.
• Pharmaceutical manufacturers will now be expected to provide U.S. citizens with “Most-Favored-Nation” (MFN) pricing, meaning the lowest price available to any similar country.
• The Secretary of Health and Human Services will create a system for Americans to purchase medications directly from manufacturers at Most-Favored-Nation pricing.
• If manufacturers do not comply, Health and Human Services (HHS) is directed to propose rules to enforce MFN pricing and take additional steps to eliminate anticompetitive practices and reduce consumer costs.

While this Executive Order signifies a new era for pharmacy benefit management, Drexi is already operating in that future. We provide:

• Lowest-Cost Medications, Powered by Intelligence
  Drexi’s proprietary technology already identifies the lowest cost medication at the point of fill. Our system compares prices across an expansive pharmacy network to ensure members and plans never overpay.
• Proven Global Sourcing Experience
  While most PBMs are only now exploring international drug importation, Drexi has been doing it for years. We provide safe, compliant access to medications from the same factories used by countries like Canada and the United Kingdom. This ensures significant cost savings without compromising safety or quality.
• Transparent Pricing and Complete Pass-Through
  Drexi returns 100 percent of all discounts and manufacturer rebates to the plan. Our model removes traditional markups and spread pricing. There are no hidden incentives. Just clarity and value.
• Member Access Without Restrictions
  With thousands of pharmacies in our network, Drexi gives members the flexibility to access medications in a way that works for them. We support both retail and mail-order fulfillment and include international options for evengreater savings.
•  Poised for Growth as Reform Expands
  The Executive Order opens new opportunities for direct access and lower pricing. Drexi is already structured to meet those opportunities head-on and deliver even more value to brokers, employer groups, and the members they serve.

While Others Pivot, Drexi Stays the Course

As President Trump stated:

In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory...Four times, five times different.

Drexi was created to solve this exact problem, and we’ve been doing it for more than a decade. Our model prioritizes transparency, fairness, and unrestricted access. While others are adjusting to meet new expectations, Drexi is partnering with brokers and self-funded employer groups who are already benefiting from meaningful change and massive savings.

Drexi isn’t reacting to policy. We’ve always operated with these principles. What the Executive Order is asking of the industry, we’ve been doing from the beginning, giving employers and members fair, transparent, and affordable access to their prescriptions. It’s only going to get better from here.
‍
— Anthony Masotto, EVP and General Manager, Drexi

Your Clients Deserve a PBM That’s Already Delivering on What the Industry Is Just Now Promising

The prescription benefit space is evolving quickly. Brokers who want to bring immediate value to their clients have a choice. Drexi is already delivering on what the government is just starting to push forward. We are ready to help your clients achieve real savings, compliance confidence, and a better member experience.

Let’s have a conversation about how Drexi can bring lasting value to your clients.
Schedule time with our team today and discover the smarter way forward in pharmacy benefits.
‍

Sources:

1.     Kaiser Family Foundation – Poll: https://www.kff.org/health-costs/poll-finding/public-opinion-on-prescription-drugs-and-their-prices/